Recorded Chinese product: 磷酸哌喹片磷酸哌喹片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 海南全星制药有限公司Chinese legal name: 海南全星制药有限公司
主要成分Active Ingredients
- 哌喹Pai Kui
药物知识说明
哌喹是一种在国家药监局注册认定的药品。该药品含有哌喹-d37d14be等成分。
该药品关联的活性成分包括：哌喹Pai Kui。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：海南全星制药有限公司Chinese legal name: 海南全星制药有限公司。
您可以探索含有相同成分的其他药品：哌喹-d37d14be成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 磷酸哌喹片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 哌喹Pai Kui.
Manufacturers recorded for this product: 海南全星制药有限公司Chinese legal name: 海南全星制药有限公司.
Explore other medicines containing the same ingredient: 哌喹 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 磷酸哌喹片Recorded Chinese product: 磷酸哌喹片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 0.25g0.25 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 海南全星制药有限公司Chinese legal name: 海南全星制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H46020199
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H46020199
Manufacturer
Chinese legal name: 海南全星制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H46020199
生产企业
海南全星制药有限公司(国产)
适应症
主要用于疟疾症状的抑制性预防，也可用于疟疾的治疗。此外并有延缓矽肺病情进展的作用，现正试用于矽肺的防治。
用法用量
成人常用量口服。剂量按哌喹计。 1.抑制性预防疟疾。每月服0.6g，1月1次，临睡前服，可连服4~6个月，但不宜超过6个月。 2.治疗疟疾。本品对耐氯喹虫株所致的恶性疟有根治作用，但作用缓慢，宜在奎宁、青蒿素、咯萘啶控制症状后继用本品。首次0.6g，第2、3日分别服0.6g及0.3g，总量1.2~2.5g。 3.矽肺的防治。预防，每次服0.5g，10~15日1次，1月量1~1.5g；治疗.每次0.3~0.75g，每周1次，1月量2g，半年为一疗程。间歇1月后，进行第二疗程，总疗程3~5年。
不良反应
可引起头昏，嗜睡，乏力，胃部不适，面部和唇周麻木，对心血管系统的毒性明显小于氯喹。
禁忌
严重急性肝、肾及心脏疾患禁用。
注意事项
孕妇及肝功能不全者慎用。
贮藏
遮光，密封保存。
规格
0.25g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.